FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180908193> ?p ?o ?g. }

• W3180908193 endingPage "CT210" @default.
• W3180908193 startingPage "CT210" @default.
• W3180908193 abstract "Abstract The SOS1i::KRAS inhibitor BI 1701963 is the first direct RAS signaling modifier to enter phase I clinical trials both as a monotherapy as well as in combination. SOS1::KRAS inhibitors exhibit activity against a broad spectrum of KRAS alleles, including the major G12D/V/C and G13D oncoproteins, while sparing the interaction of KRAS with SOS2. Here, we present pre-clinical data showing enhanced pathway modulation and synergistic anti-tumor effects following vertical pathway inhibition of BI 1701963 in combination with mitogen-activated protein kinase inhibitors (MEKi; trametinib and BI 3011441) or KRAS G12C inhibitors (MRTX849 and BI 1823911). Furthermore, SOS1::KRAS inhibitor treatment sensitizes tumor cells to increased DNA damage in combination with irinotecan. Our results highlight the suitability of SOS1::KRAS inhibitors as a backbone in combination therapies targeting KRAS-dependent tumors. Pre-clinical combination data supported the start of multiple phase I trials investigating the safety, tolerability, recommended dose and preliminary efficacy of BI 1701963 alone and in combination with other anti-cancer agents. Combination trials of BI 1701963 with MEKi include cohorts of patients with KRAS mutant solid tumors, such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), cholangiocarcinoma and pancreatic adenocarcinoma. Trials exploring the combination of BI 1701963 with irreversible KRAS G12C inhibitors (MRTX849 and BI 1823911) will include cohorts of patients with KRAS G12C mutant NSCLC and CRC. In a further study, the combination of BI 1701963 with irinotecan is being evaluated in patients with KRAS mutant CRC. Primary endpoints include dose-limiting toxicities, treatment-emergent or -related adverse events. Secondary endpoints include pharmacokinetic and pharmacodynamic properties of combination regimens and preliminary efficacy. Citation Format: Marco H. Hofmann, Hengyu Lu, Ulrich Duenzinger, Daniel Gerlach, Francesca Trapani, Annette A. Machado, Joseph R. Daniele, Irene Waizenegger, Michael Gmachl, Dorothea Rudolph, Christopher P. Vellano, Marcelo Marotti, Vitomir Vucenovic, Timothy P. Heffernan, Joseph R. Marszalek, Mark P. Petronczki, Norbert Kraut. Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT210." @default.
• W3180908193 created "2021-07-19" @default.
• W3180908193 creator A5002724373 @default.
• W3180908193 creator A5012829421 @default.
• W3180908193 creator A5018745068 @default.
• W3180908193 creator A5023344154 @default.
• W3180908193 creator A5044601694 @default.
• W3180908193 creator A5045554885 @default.
• W3180908193 creator A5048521277 @default.
• W3180908193 creator A5052456593 @default.
• W3180908193 creator A5056562930 @default.
• W3180908193 creator A5056893617 @default.
• W3180908193 creator A5061124280 @default.
• W3180908193 creator A5062735715 @default.
• W3180908193 creator A5065005644 @default.
• W3180908193 creator A5065349307 @default.
• W3180908193 creator A5074917154 @default.
• W3180908193 creator A5080319134 @default.
• W3180908193 creator A5086143409 @default.
• W3180908193 date "2021-07-01" @default.
• W3180908193 modified "2023-10-16" @default.
• W3180908193 title "Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan." @default.
• W3180908193 doi "https://doi.org/10.1158/1538-7445.am2021-ct210" @default.
• W3180908193 hasPublicationYear "2021" @default.
• W3180908193 type Work @default.
• W3180908193 sameAs 3180908193 @default.
• W3180908193 citedByCount "7" @default.
• W3180908193 countsByYear W31809081932021 @default.
• W3180908193 countsByYear W31809081932022 @default.
• W3180908193 countsByYear W31809081932023 @default.
• W3180908193 crossrefType "journal-article" @default.
• W3180908193 hasAuthorship W3180908193A5002724373 @default.
• W3180908193 hasAuthorship W3180908193A5012829421 @default.
• W3180908193 hasAuthorship W3180908193A5018745068 @default.
• W3180908193 hasAuthorship W3180908193A5023344154 @default.
• W3180908193 hasAuthorship W3180908193A5044601694 @default.
• W3180908193 hasAuthorship W3180908193A5045554885 @default.
• W3180908193 hasAuthorship W3180908193A5048521277 @default.
• W3180908193 hasAuthorship W3180908193A5052456593 @default.
• W3180908193 hasAuthorship W3180908193A5056562930 @default.
• W3180908193 hasAuthorship W3180908193A5056893617 @default.
• W3180908193 hasAuthorship W3180908193A5061124280 @default.
• W3180908193 hasAuthorship W3180908193A5062735715 @default.
• W3180908193 hasAuthorship W3180908193A5065005644 @default.
• W3180908193 hasAuthorship W3180908193A5065349307 @default.
• W3180908193 hasAuthorship W3180908193A5074917154 @default.
• W3180908193 hasAuthorship W3180908193A5080319134 @default.
• W3180908193 hasAuthorship W3180908193A5086143409 @default.
• W3180908193 hasConcept C121608353 @default.
• W3180908193 hasConcept C126322002 @default.
• W3180908193 hasConcept C143998085 @default.
• W3180908193 hasConcept C184235292 @default.
• W3180908193 hasConcept C185592680 @default.
• W3180908193 hasConcept C197934379 @default.
• W3180908193 hasConcept C2776087337 @default.
• W3180908193 hasConcept C2776256026 @default.
• W3180908193 hasConcept C2776999253 @default.
• W3180908193 hasConcept C2778375690 @default.
• W3180908193 hasConcept C2780259306 @default.
• W3180908193 hasConcept C2781187634 @default.
• W3180908193 hasConcept C2781249067 @default.
• W3180908193 hasConcept C502942594 @default.
• W3180908193 hasConcept C526805850 @default.
• W3180908193 hasConcept C535046627 @default.
• W3180908193 hasConcept C55493867 @default.
• W3180908193 hasConcept C57074206 @default.
• W3180908193 hasConcept C71924100 @default.
• W3180908193 hasConcept C98274493 @default.
• W3180908193 hasConceptScore W3180908193C121608353 @default.
• W3180908193 hasConceptScore W3180908193C126322002 @default.
• W3180908193 hasConceptScore W3180908193C143998085 @default.
• W3180908193 hasConceptScore W3180908193C184235292 @default.
• W3180908193 hasConceptScore W3180908193C185592680 @default.
• W3180908193 hasConceptScore W3180908193C197934379 @default.
• W3180908193 hasConceptScore W3180908193C2776087337 @default.
• W3180908193 hasConceptScore W3180908193C2776256026 @default.
• W3180908193 hasConceptScore W3180908193C2776999253 @default.
• W3180908193 hasConceptScore W3180908193C2778375690 @default.
• W3180908193 hasConceptScore W3180908193C2780259306 @default.
• W3180908193 hasConceptScore W3180908193C2781187634 @default.
• W3180908193 hasConceptScore W3180908193C2781249067 @default.
• W3180908193 hasConceptScore W3180908193C502942594 @default.
• W3180908193 hasConceptScore W3180908193C526805850 @default.
• W3180908193 hasConceptScore W3180908193C535046627 @default.
• W3180908193 hasConceptScore W3180908193C55493867 @default.
• W3180908193 hasConceptScore W3180908193C57074206 @default.
• W3180908193 hasConceptScore W3180908193C71924100 @default.
• W3180908193 hasConceptScore W3180908193C98274493 @default.
• W3180908193 hasIssue "13_Supplement" @default.
• W3180908193 hasLocation W31809081931 @default.
• W3180908193 hasOpenAccess W3180908193 @default.
• W3180908193 hasPrimaryLocation W31809081931 @default.
• W3180908193 hasRelatedWork W1964478207 @default.
• W3180908193 hasRelatedWork W1996349887 @default.
• W3180908193 hasRelatedWork W2120434825 @default.
• W3180908193 hasRelatedWork W2435704186 @default.
• W3180908193 hasRelatedWork W2804957989 @default.
• W3180908193 hasRelatedWork W2967069704 @default.

• next